TRELSTAR - About Prostate Cancer

Cancer of the prostate begins in the prostate’s glandular tissue, which is a part of the reproductive system. Since only men have a prostate gland, only they are prone to this kind of cancer.

Most of the cancers involving the prostate are called adenocarcinomas. Often, a malignant tumor begins somewhere in the outer section of the prostate gland. As it grows, it could spread to the inner section of the gland. If the cancer has not spread, it is termed “localized prostate cancer.” The good news is that this type of cancer is slow-growing, giving it more of a chance to be successfully managed. In fact, nearly all (99%) men who are diagnosed with it survive at least five years following their diagnosis. If caught early, the chance of surviving the disease may be increased.

As the cancer grows, it could squeeze the urethra, which is surrounded by the prostate. This may cause such symptoms as difficulty in urinating. Although not a definite sign of prostate cancer, this is often one of the first symptoms that someone may experience if they have prostate cancer. Prostate cancer could spread to the lymph nodes, some bones (particularly those of the hip and lower back), lungs, and, sometimes, even the brain. This is called metastatic prostate cancer.

Learn more about some symptoms or risk factors of prostate cancer.

Prostate Cancer Facts

Indications and Usage
TRELSTAR^® Depot and TRELSTAR^® LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.

Safety Information

The most commonly reported adverse events associated with the use of TRELSTAR^® Depot/TRELSTAR^® LA included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock and angioedema have been received since 1986 (global experience) . As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, spinal cord compression, or urethral or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed.